share_log

Biogen Has Agreed To Acquire Human Immunology Biosciences For $1.15B Upfront And Up To $650M In Potential Milestone Payments

Biogen Has Agreed To Acquire Human Immunology Biosciences For $1.15B Upfront And Up To $650M In Potential Milestone Payments

Biogen已同意以11.5億美元的預付金和高達6.5億美元的潛在里程碑付款收購人類免疫學生物科學
Benzinga ·  05/22 19:32
  • Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases
  • Felzartamab is an investigational anti-CD38 monoclonal antibody that, through its cell depletion approach, has demonstrated clinical proof of concept in rare immune-mediated indications, with plans to advance to Phase 3
  • Proposed acquisition builds on Biogen capabilities in immunology with plans to combine Human Immunology Biosciences expertise in immune-mediated indications with Biogen's global development and commercial experience in rare diseases
  • 該交易將包括費爾扎他單抗,這是一種潛在的同類首創候選治療藥物,有望成爲一系列免疫介導疾病的管道產品
  • Felzartamab是一種在研的抗CD38單克隆抗體,通過其細胞耗盡方法,已在罕見的免疫介導適應症中證明了臨床概念的證實,並計劃進入3期
  • 擬議的收購建立在Biogen在免疫學領域的能力基礎上,並計劃將人類免疫學生物科學在免疫介導適應症方面的專業知識與Biogen在罕見疾病領域的全球開發和商業經驗相結合

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論